DEXA Scan: What It Measures in Bone, Muscle and Visceral Fat

A DEXA scan is not one number. It may mean a central hip-and-spine study for bone mineral density, or a whole-body scan that estimates fat, lean tissue and regional distribution. Both use two low-dose X-ray energies, but they answer different questions and may not be included in the same appointment.

The useful interpretation begins before the scan: are you estimating fracture risk, checking lean-mass loss during treatment, or tracking a body-composition intervention? Without that decision, a T-score, body-fat percentage or lean-mass result reported to a decimal can look more precise and actionable than it is.

Clinical and editorial review: August 21, 2026. On that date we reviewed the Spanish searches “densitometría DEXA”, “DEXA composición corporal” and “densitometría ósea”, plus the English searches “DEXA scan body composition”, “bone density scan” and “DEXA visceral fat”. English results contain many commercial scan services calling DXA a universal gold standard; Spanish results focus mainly on osteoporosis. The useful gap is to connect bone, composition and function and state where each measurement ends. This article is educational and does not replace medical assessment.

What a DEXA scan measures—and what it does not

Result	What it represents	What it cannot prove alone
BMD in g/cm²	Projected bone mineral per area at spine, hip or forearm	Complete microarchitecture, collagen quality or total personal fracture risk
T-score	Standard deviations from a young-adult reference	Your “bone age” or a treatment decision by itself
Z-score	Standard deviations from an age- and sex-matched reference	Automatic osteoporosis in a younger adult
Lean mass	Non-fat, non-mineral tissue, regionally and in total	Pure contractile muscle, muscle quality, strength or power
ALM/ALMI	Lean mass in arms and legs, absolute or height-adjusted	Sarcopenia without strength and clinical context
Total and regional fat	Estimated mass and percentage in trunk, limbs, android and gynoid regions	Inflammation, liver fat or individual cardiometabolic risk
Visceral adipose tissue	Algorithmic estimate of internal abdominal fat	Direct anatomical segmentation like CT or MRI

DXA is the technically preferred acronym for dual-energy X-ray absorptiometry, although DEXA is the common search term. Bone DXA measures areal, not volumetric, density. Whole-body software assigns pixels to bone mineral, fat or lean tissue using manufacturer models. Results may therefore stop being comparable when the scanner, software or region placement changes.

T-score, Z-score, osteopenia and osteoporosis

In postmenopausal women and men aged 50 or older, the T-score is preferred. ISCD states that a score of -2.5 or lower at the femoral neck, total hip, lumbar spine or, in selected circumstances, the 33% radius can establish densitometric osteoporosis. Between -1 and -2.5 is low bone mass; “osteopenia” does not automatically mean high fracture risk.

Before menopause and in men younger than 50, the Z-score is preferred. A Z-score of -2.0 or below is described as “below the expected range for age”. Bone density alone cannot diagnose osteoporosis in men under 50.

NIAMS summarizes the population effect clearly: fracture risk rises about 1.5- to 2-fold for every one-point decrease in T-score. That is a relative gradient, not a personal probability. Age, falls, prior fractures, glucocorticoids, menopause, smoking, low weight and an absolute-risk model such as FRAX may matter as much as the score. A low-trauma fracture can warrant evaluation and treatment even above -2.5.

Who may benefit from a bone density scan

Screening recommendations differ by health system. The 2025 USPSTF recommends screening women aged 65 or older and younger postmenopausal women at increased risk after clinical assessment; it finds evidence insufficient for population screening in men. The 2025 international best-practice guideline suggests considering DXA in women from 65, men over 70 and adults from 50 with risk factors. These are not interchangeable rules: local guidance and the clinical question matter.

• A low-trauma fracture, height loss or suspected vertebral fracture.
• Menopause plus added risk, especially early or surgical menopause.
• Glucocorticoids, aromatase inhibitors, androgen-deprivation therapy or other bone-losing medication.
• Low body weight, malabsorption, bariatric surgery, hyperparathyroidism, hypogonadism, systemic inflammatory disease or immobilization.
• Starting or monitoring osteoporosis treatment when the result can change management.

A scan cannot replace a history of falls, nutrition, medication and exercise. Good preventive medicine treats fracture risk, not the image.

Appendicular lean mass is one part of muscle health

Whole-body DEXA adds arm and leg lean tissue as appendicular lean mass (ALM) and may divide it by height squared (ALMI). In EWGSOP2, reference cutoffs for older European adults are ALM below 20 kg in men or 15 kg in women, or ALMI below 7.0 and 5.5 kg/m². They are not universal performance targets for athletes, younger people or every ancestry.

The clinical distinction matters: sarcopenia is first suspected from low strength; imaging supports low muscle quantity, and performance identifies severity. The 2025 ECTS/NCO statement concludes that imaging cannot replace functional assessment. Grip strength, five chair stands, gait speed and daily ability answer a question the scanner cannot see.

Lean mass is not identical to muscle: it includes water, skin, connective tissue and organs. A 2026 UK Biobank analysis of 32,961 participants found that DXA captured fat change reasonably but overestimated lean tissue versus MRI. In 1,928 people rescanned after about 2.5 years, MRI detected a 4-5% muscle decline that DXA did not. That limitation matters during major weight loss or GLP-1 treatment: protein intake, resistance load and function need tracking too.

Visceral fat and android-to-gynoid distribution

The android region approximates the abdomen; the gynoid region covers hips and upper thighs. Some scanners estimate visceral adipose tissue inside the android region. Read it as a contextual trend alongside waist circumference, blood pressure, HbA1c, triglycerides and ApoB, not as a stand-alone diagnosis.

In a matched comparison of 4,558 UK Biobank participants, DXA and MRI agreed well for total fat and lean tissue but much less well for visceral fat, with variability above 20%. CT and MRI better separate visceral and subcutaneous fat, muscle infiltration and individual muscle volume. CT brings more radiation; MRI brings more cost and time. A full-body MRI should not be ordered merely to obtain a body-fat percentage.

DEXA versus BIA, CT and MRI

Method	Strength	Limit	Best fit
DEXA	Bone and regional composition at very low dose	2D model; lean mass and VAT are estimates	Bone question or standardized composition follow-up
BIA	Fast, inexpensive, no radiation	Equation-, hydration- and device-dependent	Frequent tracking under a consistent protocol
CT	Detailed muscle, fat and infiltration	Higher radiation; not justified solely for composition	Use an already indicated scan or specialist setting
MRI	3D tissue volume and quality without radiation	Cost, time and access	Research or a complex clinical question
Function tests	Measure what the person can do	Effort- and protocol-dependent	Always when muscle, autonomy or performance is the goal

Protocol, radiation and a comparable repeat scan

The scan usually takes 5-15 minutes. Bone assessment commonly covers lumbar spine and hip; selected cases add forearm or lateral vertebral assessment. Whole-body composition requires lying still, with metal removed from the scanned field.

The IAEA places a typical hip, spine or whole-body DXA examination at roughly 1-10 microsieverts, depending on scanner and mode. The dose is very low but not zero. Tell the center about pregnancy or possible pregnancy, recent contrast or radiopharmaceuticals. Prostheses, degenerative change, fractures, calcification, movement and scanner table limits can distort or prevent analysis.

For longitudinal body composition, use the same scanner and ideally the same operator, time of day, hydration, food state, recent exercise, clothing and bladder status. ISCD requires facilities to establish a least significant change (LSC). If the difference does not exceed measurement error, it should not be sold as real fat loss or muscle gain.

How often should DEXA be repeated?

There is no universal “longevity” schedule. Bone-density timing depends on age, baseline BMD, treatment and expected rate of change. Intervals may be shorter with glucocorticoids, osteoanabolic therapy, bariatric surgery, immobilization, malabsorption or surgical menopause. In stable conditions, repeating too soon mostly measures noise. A follow-up report should identify the prior study and regions, the facility LSC and whether change is statistically significant.

For body composition, a baseline and a later scan after an intervention long enough to matter can be useful; scanning every few weeks rarely changes care. Pair the result with waist, weight, functional strength, training, nutrition and symptoms.

Decision table: which assessment answers the question?

Question	Reasonable option	What to add
Is osteoporosis or fracture risk the concern?	Central hip-and-spine DXA	Fracture/fall history, FRAX and secondary causes
Is there weakness, weight loss or suspected sarcopenia?	Function first; DXA or BIA for quantity	Grip, chair stands, gait, nutrition and underlying disease
Is substantial weight loss expected with diet, surgery or medication?	Baseline composition and follow-up if it changes care	Strength, protein, symptoms and rate of loss
Is abdominal fat the target?	Waist and biomarkers; DXA as an added layer	Blood pressure, HbA1c, lipids and hormonal context
Is precise muscle quality or infiltration required?	MRI or CT only when indicated	Specialist interpretation and function
Is it curiosity with no planned decision?	A scan is probably unnecessary	Define what result would change behavior first

Risks, limitations and red flags

Direct harm is small: DEXA is painless and uses little radiation. More common risks are indirect—false reassurance, anxiety over decimals, artifact-driven misclassification, incompatible scanner comparisons or repeat testing that cannot change care. Pregnancy is a contraindication for elective body-composition DXA; any exceptional imaging decision belongs to a radiology and clinical team.

A fall followed by hip pain and inability to bear weight, severe sudden spinal pain, rapid height loss, progressive weakness, unintentional weight loss or repeated fractures needs clinical assessment; a scheduled DEXA does not replace radiographs, laboratory testing or urgent care. During weight-loss treatment, dizziness, persistent vomiting, very low intake or rapidly falling strength should trigger a protocol review.

Frequently asked questions

Are DEXA and bone density scans the same?

They share technology, but central hip/spine DXA and whole-body composition are different protocols. Confirm which regions and outputs are included.

What T-score means osteoporosis?

In postmenopausal women and men aged 50 or older, -2.5 or lower at a valid site establishes densitometric osteoporosis. Clinical risk and fractures may change management before that threshold.

Does DEXA measure real muscle?

It estimates lean tissue. Muscle health requires strength and performance; an image cannot measure the ability to rise, carry or walk.

Does DEXA accurately measure visceral fat?

It provides a useful estimate for trends but not the anatomical segmentation of CT or MRI. There is no universal DEXA threshold that independently diagnoses cardiometabolic risk.

Do you need to fast?

Usually not for bone density. For body-composition follow-up, reproducing the same conditions matters more; follow the center's protocol.

How often should you repeat it?

When a biological change is plausible, the result can alter a decision and the difference is likely to exceed scanner error. The report should explain the interval.

Sources and certainty

• ISCD Official Adult Positions 2023: indications, T-score/Z-score, valid sites, follow-up, precision and body composition.
• International DXA best-practice guideline 2025: referral, preparation, acquisition, interpretation and quality control.
• USPSTF 2025: screening population, benefit and evidence gaps in men.
• NIAMS: T-score, Z-score and fracture-risk gradient.
• IAEA Human Health Series: DXA dose, safety and quality control.
• 2025 ECTS/NCO muscle-imaging statement: DXA, CT, MRI and why imaging cannot replace function.
• EWGSOP2: European sarcopenia algorithm for strength, mass and performance.
• UK Biobank 2026, DXA versus MRI: 32,961 participants and 1,928 repeat scans.
• UK Biobank visceral-fat validation: matched MRI, DXA and BIA in 4,558 participants.

Certainty is high for central DXA in indicated bone diagnosis and monitoring; moderate for total-fat and lean-mass measurement under a stable protocol; and limited for turning estimated lean mass or visceral fat into a stand-alone functional or cardiometabolic diagnosis.

At Progevita, body-composition testing earns its place only when it changes the plan. An assessment combines DEXA when indicated with history, biomarkers, strength, nutrition and follow-up. If you want to decide what to measure and how often, request clinical guidance.